(8 days)
IMx® Folate assay
Not Found
No
The summary describes a laboratory assay for measuring folate levels and does not mention any AI or ML components. The performance studies focus on correlation with a predicate device, which is typical for laboratory assays and does not indicate AI/ML use.
No
The device is an in vitro diagnostic assay used for measuring folic acid levels, which aids in diagnosis. It does not directly treat or prevent a disease, which is the function of a therapeutic device.
Yes
The "Intended Use / Indications for Use" section explicitly states that "Folic acid measurements are used in the diagnosis and treatment of megaloblastic anemia." This indicates that the device provides information used for diagnosis.
No
The device description clearly states it is an "ion capture assay" and mentions "calibrators" and "controls," which are physical components used in laboratory testing, not solely software.
Yes, this device is an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use explicitly states it's "intended to measure the vitamin folic acid in serum, plasma, and red blood cells." These are biological samples taken in vitro (outside the body).
- Purpose: The measurements are used "in the diagnosis and treatment of megaloblastic anemia." This indicates a medical purpose for the test results.
- Device Description: It describes an "ion capture assay for the quantitative determination of folate in human serum, plasma, or red blood cells." This further confirms it's a test performed on biological samples.
The definition of an IVD is a medical device that is used to examine specimens, such as blood, urine, or tissue, from the human body to provide information for diagnosis, monitoring, or treatment. This device clearly fits that definition.
N/A
Intended Use / Indications for Use
"Abbott AxSYM® Folate is an Ion Capture Assay intended to measure the vitamin folic acid in serum, plasma, and red blood cells. Folic acid measurements are used in the diagnosis and treatment of megaloblastic anemia."
Product codes
CGN
Device Description
"AxSYM Folate is an ion capture assay for the quantitative determination of folate in human serum, plasma, or red blood cells. AxSYM Folate is calibrated with Abbott Folate calibrators. Abbott Folate controls are assayed for the verification of the accuracy and precision of the AxSYM System."
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies
"A correlation analysis between these two assays is as follows:
| Sample Type | n | Correlation Coefficient | Slope | Standard Error of Y Estimate | Y-Intercept (ng/mL) |
|---|---|---|---|---|---|
| Serum | 261 | 0.979 | 0.991 | 0.864 | 0.5 |
| Red Blood Cells | 145 | 0.906 | 0.885 | 43.290 | 39.7 |
Key Metrics
Not Found
Predicate Device(s)
IMx® Folate assay
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 862.1295 Folic acid test system.
(a)
Identification. A folic acid test system is a device intended to measure the vitamin folic acid in plasma and serum. Folic acid measurements are used in the diagnosis and treatment of megaloblastic anemia, which is characterized by the presence of megaloblasts (an abnormal red blood cell series) in the bone marrow.(b)
Classification. Class II.
0
JUN 2 4 1997
510(k) Summary Abbott AxSYM® Folate
Summary of Safety and Effectiveness Information Supporting a Substantially Equivalent Determination
The following information as presented in the Premarket Notification [510(k)] for AxSYM Folate constitutes data supporting a substantially equivalent determination.
AxSYM Folate is an ion capture assay for the quantitative determination of folate in human serum, plasma, or red blood cells. AxSYM Folate is calibrated with Abbott Folate calibrators. Abbott Folate controls are assayed for the verification of the accuracy and precision of the AxSYM System.
Substantial equivalence has been demonstrated between the AxSYM Folate assay and the IMx® Folate assay. The intended use of both assays is for the quantitative determination of folate in human serum, plasma, or red blood cells. The dynamic ranges of the IMx Folate and AxSYM Folate assays are 0.82 to 20 ng/mL and 0.9 to 20 ng/mL respectively. A correlation analysis between these two assays is as follows:
| Sample Type | n | Correlation
Coefficient | Slope | Standard Error
of Y Estimate | Y-Intercept
(ng/mL) |
|-----------------|-----|----------------------------|-------|---------------------------------|------------------------|
| Serum | 261 | 0.979 | 0.991 | 0.864 | 0.5 |
| Red Blood Cells | 145 | 0.906 | 0.885 | 43.290 | 39.7 |
In conclusion, these data demonstrate that the AxSYM Folate assay is as safe and effective as, and is substantially equivalent to the IMx Folate assay.
Prepared and Submitted June 13, 1997 by:
Abbott Laboratories Laura L. Granitz (847) 938-0092 Senior Regulatory Specialist ADD Regulatory Affairs 200 Abbott Park Road Abbott Park, IL 60064
AxSYM Folate 510(k) June 1997 Fol-sii.lwp
Section II Page l
1
Image /page/1/Picture/2 description: The image shows the seal of the Department of Health & Human Services USA. The seal features a stylized eagle with three stripes extending from its head, representing health, hope, and service. The words "DEPARTMENT OF HEALTH & HUMAN SERVICES USA" are arranged in a circular pattern around the eagle.
JUN 2 4 1997
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
Laura L. Granitz Regulatory Specialist Abbott Laboratories, Inc. 200 Abbott Park Road, Dept. 09V6, Bldg. AP31 Abbott Park, Illinois 60064-3537
Re : K972232 Abbott AxSYM® Folate Regulatory Class: II Product Code: CGN Dated: June 13, 1997 Received: June 16, 1997
Dear Ms. Granitz:
We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. ਸੈ substantially equivalent determination assumes compliance with the Good Manufacturing Practice for Medical Devices: I General (GMP) regulation (21 CFR Part 820) and that, through periodic GMP inspections, the Food and Drug Administration (FDA) ville verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.
2
Page 2 ''
Under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88), this device may require a CLIA complexity categorization. To determine if it does, you should contact the Centers for Disease Control and Prevention (CDC) at (770) 488-7655.
This letter will allow you to begin marketing your device as ' described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to
premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsmamain.html".
Sincerely yours,
Steven Litman
Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
3
510(k) Number (if known):
KG72332
Abbott AxSYM® Folate Device Name: _________________________________________________________________________________________________________________________________________________________________
· Indications For Use:
f
Abbott AxSYM® Folate is an Ion Capture Assay intended to measure the vitamin folic acid in serum, plasma, and red blood cells. Folic acid measurements are used in the diagnosis and treatment of megaloblastic anemia.
(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
The H. Liggadon
(Division Sign-Off)
Prescription Use
(Per 21 CFR 801.109) ✓
vision of Olinical Laboratory ver-The-Counter Use
(Optional Format 1-2-96)